- The disease
- Peripheral nerve injuries caused by trauma occur when the nerves outside the brain and spinal cord are cut, stretched, or crushed. These injuries can result in loss of sensation, muscle weakness, or paralysis in the affected area. Surgical repair is typically required for complete nerve transections, and the quality of nerve healing directly affects functional recovery. Recovery can be slow and incomplete, leaving patients with long-term deficits.
- What the asset is trying to do
- Remplir is classified as a regenerative biologic. It is a collagen-based nerve wrap used during surgery to support the repair site of a damaged peripheral nerve. The product is derived from Orthocell's CelGro collagen technology platform (per Orthocell company disclosures). Rather than replacing the nerve itself, it is applied around the repair site to provide a scaffold intended to support the natural healing process.
- Efficacy benchmarks in this setting
- Remplir holds regulatory approval and is therefore not being evaluated in a pre-approval clinical trial at this time. For context on the broader setting, published data on collagen nerve conduits and wraps as a class report varying outcomes depending on gap length, nerve type, and patient factors. Direct benchmarking figures from approved comparator devices in peripheral nerve repair are not available in the provided source data and are marked . Early-stage figures from any individual study in this field are generally not statistically comparable across devices due to differences in patient populations and surgical settings.
- Commercial context
- Remplir has received regulatory approval and is a commercialised product for Orthocell (per Orthocell company disclosures). As of April 2026, Orthocell announced first sales of Remplir in the Canadian market, which the company described as a US$75 million addressable market (per ASX announcement dated 2026-04-29). A real-world study cited by the company reported a 90% success rate for Remplir, as disclosed in an ASX announcement dated 2026-04-27; the methodology and full citation for that study are . Remplir appears to be one of Orthocell's lead commercial assets based on its prominence in recent investor presentations (per ASX announcements April 2026).